Hypothalamic menin depletion accelerates systemic aging and cognitive decline, while restoration extends lifespan. Read more ...

The prevalence of obesity is steadily rising and has huge health and financial implications for society. Weight gain is due to an imbalance between dietary intake and energy expenditure and research ...

Launch follows MHLW approval of IMCIVREE for acquired hypothalamic obesity and inclusion on Japan's National Health Insurance ...

Functional hypothalamic amenorrhea in mid-adulthood was associated with an increased risk of coronary heart disease, ...

Rhythm Pharmaceuticals' (RYTM) early Imcivree feedback from four pediatric endocrinologists managing hypothalamic obesity patients is encouraging, RBC said in a note Thursday. RBC ...

Obesity associated with hypothalamic dysfunction was initially described in patients with craniopharyngioma. Hypothalamic obesity may also result from brain radiation, infection (eg, tuberculosis), ...

Please provide your email address to receive an email when new articles are posted on . Setmelanotide was linked to reduction in BMI at 52 weeks compared with placebo for patients with acquired ...

The brain controls the release of glucose in a wide range of stressful circumstances, including fasting and low blood sugar levels. However, less attention has been paid to its role in day-to-day ...

Selective regions of the brain, including the hypothalamus, are capable of gathering information on the body's nutritional status in order to implement appropriate behavioral and metabolic responses ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved an expanded indication for setmelanotide for acquired hypothalamic obesity. The drug conferred ...

Rhythm Pharmaceuticals, Inc. ( RYTM) announced the commercial launch of Imcivree (setmelanotide) in Japan for acquired hypothalamic obesity, following its inclusion on the country's National Health ...